<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The second most frequent malignant tumor of the bone after osteosarcoma, chondrosarcoma is subdivided in conventional type, mesenchymal, clear cell, and the dedifferentiated subtype. Each of these pathological entities has a particular clinical behavior. For most, surgery remains the sole valid option. However, efficient systemic therapy options for advanced and metastatic cases are scarce. This short review is aimed at describing the latest options presented by current literature in these cases. Most of the data is derived from preclinical trials, but some drugs were also included in clinical research as far as phase two trials. After reviewing this data, it could be concluded that the future in unresectable or metastatic chondrosarcoma is personalized medicine and that more specific biomarkers to aid the choice are necessary.</p></abstract>

The second most frequent malignant tumor of the bone after osteosarcoma, chondrosarcoma is subdivided in conventional type, mesenchymal, clear cell, and the dedifferentiated subtype. Each of these pathological entities has a particular clinical behavior. For most, surgery remains the sole valid option. However, efficient systemic therapy options for advanced and metastatic cases are scarce. This short review is aimed at describing the latest options presented by current literature in these cases. Most of the data is derived from preclinical trials, but some drugs were also included in clinical research as far as phase two trials. After reviewing this data, it could be concluded that the future in unresectable or metastatic chondrosarcoma is personalized medicine and that more specific biomarkers to aid the choice are necessary.

Targeted therapy options for chondrosarcoma - a preclinical perspective

“Carol Davila” University of Medicine and Pharmacy

Romanian Journal of Orthopaedic Surgery and Traumatology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Targeted therapy options for chondrosarcoma - a preclinical perspective"}

The second most frequent malignant tumor of the bone after osteosarcoma, chondrosarcoma is subdivided in conventional type, mesenchymal, clear cell, and the...

Targeted therapy options for chondrosarcoma - a preclinical perspective

Publié en ligne: 13 juin 2019

Pages: 52 - 55

DOI: https://doi.org/10.2478/rojost-2019-0011

Mots clés
chondrosarcoma, targeted therapy, systemic therapy

© 2019 Cornelia Nitipir et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Targeted therapy options for chondrosarcoma - a preclinical perspective

Publié en ligne: 13 juin 2019

Pages: 52 - 55

DOI: https://doi.org/10.2478/rojost-2019-0011

Mots cléschondrosarcoma, targeted therapy, systemic therapy

© 2019 Cornelia Nitipir et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
chondrosarcoma, targeted therapy, systemic therapy